BioMed Research International

BioMed Research International / 2017 / Article

Review Article | Open Access

Volume 2017 |Article ID 3971259 | 10 pages | https://doi.org/10.1155/2017/3971259

A Meta-Analysis of the Association between DNMT1 Polymorphisms and Cancer Risk

Academic Editor: Jinsong Ren
Received29 Nov 2016
Accepted20 Mar 2017
Published03 Apr 2017

Abstract

Previous studies have examined the associations of DNA methyltransferase 1 (DNMT1) polymorphisms, including single nucleotide polymorphisms rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G), with cancer risk. However, the results are inconclusive. The aim of this meta-analysis is to elucidate the associations between DNMT1 polymorphisms and cancer susceptibility. The PubMed, Embase, Web of Science, and Chinese National Knowledge Infrastructure databases were searched systematically to identify potentially eligible reports. Odd ratios and 95% confidence intervals were used to evaluate the strength of association between three DNMT1 polymorphisms and cancer risk. A total of 16 studies were finally included in the meta-analysis, namely, nine studies of 3378 cases and 4244 controls for rs16999593, 11 studies of 3643 cases and 3866 controls for rs2228611, and three studies of 1343 cases and 1309 controls for rs2228612. The DNMT1 rs2228612 (A/G) polymorphism was significantly related to cancer risk in the recessive model. The meta-analysis also suggested that DNMT1 rs16999593 (T/C) may be associated with gastric cancer, while rs2228611 (G/A) may be associated with breast cancer. In future research, large-scale and well-designed studies are required to verify these findings.

1. Introduction

DNA methylation is one of the most commonly occurring epigenetic events in the mammalian genome. DNA methyltransferases (DNMTs) are critical to establishing and maintaining DNA methylation patterns by converting cytosine residues to 5-methylcytosine (5mC) in cytosine–guanine (CpG) dinucleotides [1, 2]. The DNMT family comprises three active forms: DNMT1, DNMT3A, and DNMT3B. DNMT1 is the major enzyme responsible for methylation maintenance [3, 4], while DNMT3A and DNMT3B are thought to function in de novo methylation rather than in methylation maintenance [3, 4].

DNMT1 is located on human chromosome 19p13.2 and encodes a protein comprising 1632 amino acids, which may be implicated in occurrence progression and prognosis of the cancer. DNMT1 consists of three major structural elements: an N-terminal regulatory domain that is necessary for the localization of DNMT1; a C-terminal catalytic domain that is involved in the binding of substrates; and a central linker that contains repeated glycine-lysine dipeptides [5]. Genetic variation caused by single nucleotide polymorphisms (SNPs) is the most common form of altered gene structure. The most commonly studied DNMT1 SNPs are rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G), which are present in coding regions and, therefore, may influence DNMT1 expression.

In recent years, various studies have indicated that DNMT1 polymorphisms may play pivotal roles in carcinogenesis. The SNPs rs16999593 (T/C) and rs2228612 (G/A) were initially found to be associated with risk of breast cancer [6, 7], while SNP rs2228611 (A/G) was linked to gastric cancer [8]. Subsequently, a number of studies have concentrated on the relationships between DNMT1 polymorphisms and risks of different cancers [6, 7, 921]. However, the results from these studies are inconsistent.

Until now, no meta-analysis has been carried out to investigate the relation of the three DNMT1 polymorphisms (rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G)) with risk of cancer. Individual studies have lacked the ability to obtain overall reliable conclusions because of limited sample sizes and/or variations in ethnicities. To obtain further insights into the roles of DNMT1 polymorphisms in carcinogenesis, we mainly performed a meta-analysis on the associations between these three SNPs and cancer risk.

2. Materials and Methods

2.1. Search Strategy

We systematically searched the PubMed, Embase, Web of Science, and Chinese National Knowledge Infrastructure databases using different combinations of the search terms “DNMT1 or DNA methyltransferase 1,” “polymorphism or mutation or variant,” and “cancer or neoplasm or tumor.” The search was last updated on 06 June 2016. When overlapping data were found, only the largest and latest study was selected. We contacted the authors and requested their specific raw data when the data provided in the published article were not sufficient.

2.2. Inclusion and Exclusion Criteria

Studies were included when they met the following criteria: case-control study; the subject was the association of DNMT1 polymorphisms (rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G)) with risk of cancer; and essential information on genotype or allele frequencies was available to assess the odds ratios (ORs) and 95% confidence intervals (CIs). Exclusion criteria included review articles; systematic reviews and meta-analyses; animal studies; sample size less than 100; and scarce or insufficient information on genotype or allele frequencies for the rs16999593 (T/C), rs2228611 (G/A), or rs2228612 (A/G) polymorphisms of DNMT1 despite us contacting the authors.

2.3. Data Extraction

Two of the authors (HL and JL) independently selected the articles and extracted the original data using a standardized and consistent method. The following information was collected from each study: first author, year of publication, ethnicity of the subjects, cancer type, numbers of cases and controls, and genotyping methods. Conflicts were resolved after discussion and consensus was finally reached on all the extracted information.

2.4. Statistical Analysis

All statistical analyses were conducted using STATA software (version 12.0; Stata Corp LP, College Station, TX). ORs and their corresponding 95% CIs were employed to assess the strength of relationships between the DNMT1 polymorphisms and cancer risk. values < 0.05 were considered as statistically significant. Heterogeneity was calculated using the statistic ( value < 0.10 indicates significant heterogeneity among studies) and -squared value. The Mantel-Haenszel fixed-effects model was used to calculate the pooled ORs when the heterogeneity of studies was not significant. Otherwise, the DerSimonian and Laird random-effects model was used. We conducted the sensitivity analysis to explore heterogeneity when significant heterogeneity existed. Subgroup analysis was applied to explore the effects of cancer type and genotyping method. In addition, Begg’s test and Egger’s test were performed to evaluate publication bias; values < 0.05 for Begg’s and Egger’s tests indicate significant publication bias.

3. Results

3.1. Characteristics of the Studies

This meta-analysis was organized according to the PRISMA (Supplementary File 1 in Supplementary Material available online at https://doi.org/10.1155/2017/3971259). A detailed flow chart of the study selection process is shown in Figure 1. A total of 215 potentially relevant articles were found by searching the four databases and after removing duplicates. Altogether 187 publications were excluded mainly due to no relevance, animal not human experiments, reviews, or meeting abstract. The 28 remaining articles were evaluated further for eligibility. Finally, 16 articles were included in the present meta-analysis [621].

The baseline characteristics of the 16 included studies are summarized in Table 1. Among them, nine articles containing 3378 cases and 4244 controls surveyed the association between rs16999593 (T/C) and cancer risk [6, 7, 915]; 11 studies on the relation between rs2228611 (G/A) and cancer risk included 3643 cases and 3866 controls [68, 10, 11, 13, 14, 1821]; and three publications containing 1343 cases and 1309 controls explored the correlation of rs2228612 (A/G) with cancer risk [7, 16, 17]. The populations surveyed in the nine rs16999593 (T/C) studies were all Chinese [6, 7, 915]. In the rs2228611 (G/A) studies, nine of the populations were Chinese [6, 7, 10, 11, 13, 14, 1921], one was Iranian [8], and one was Polish [18]. In the rs2228612 (A/G) studies the populations were either Caucasian [16] or Chinese [7, 17]. The genotyping methods used to detect the DNMT1 polymorphisms included sequencing, MassARRAY, PCR-RFLP, MALDI-TOF, TaqMan, and SNPlex [621]. We used subgroup analyses to explore the effects of different cancer types and genotyping methods on the associations of increased risk of cancer with the DNMT1 rs16999593 (T/C) and rs2228611 (G/A) polymorphisms. We did not perform subgroup analysis for rs2228612 (A/G) because of the limited number of articles that was available.


AuthorYearEthnicityCancer typeGenotyping methodCaseControl
TotalMMWMWWTotalMMWMWW

For DNMT1 rs16999593 T/C polymorphism
Wang [12]2014ChineseCervical cancerSequencing1004844810070255
Gao [13]2015ChineseGastric cancerSequencing3101801121842028111722
Li [14]2015ChineseEsophageal cancerMassARRAY258138804026012710924
He et al. [11]2014ChineseProstate cancerMassARRAY15594538155736715
Sun [7]2012ChineseBreast cancerMassARRAY132742522429144050420228
Xiang et al. [6]2010ChineseBreast cancerPCR-RFLP305239642314220895
Jiang et al. [9]2012ChineseGastric cancerSequencing4472831442096165927329
Yang et al. [10]2012ChineseGastric cancerMALDI-TOF24214189122941968315
Tao et al. [15]2015ChineseBreast cancerSequencing23468164230018010515
For DNMT1 rs2228611 G/A polymorphism
Gao [13]2015ChineseGastric cancerSequencing3101671281542023216325
Li [14]2015ChineseEsophageal cancerMassARRAY258131854226011911328
He et al. [11]2014ChineseProstate cancerMassARRAY155826112155796412
Xiang et al. [6]2010ChineseBreast cancerPCR–RFLP3051251493131415412139
Yang et al. [21]2016ChineseRenal cell carcinomaPCR–RFLP2931521172429313913321
Yang et al. [10]2012ChineseGastric cancerMALDI-TOF24213297132851609926
Sun [7]2012ChineseBreast cancerMassARRAY6783412795873336930361
Mostowska et al. [18]2013PolishOvarian cancerPCR–RFLP159287457210449472
Xi et al. [19]2014ChineseBreast cancerMALDI-TOF8103853626384843234373
Lin et al. [20]2015ChineseBreast cancerMALDI-TOF233107109172361209422
Khatami et al. [8]2009IranianGastric cancerPCR–RFLP200345016112326218
For DNMT1 rs2228612 A/G polymorphism
Sun [7]2012ChineseBreast cancerMassARRAY675254273148731308290133
Chang et al. [17]2014ChineseEsophageal cancerSNPlex13752562935710020057
Chang et al. [17]2014ChineseStomach cancerSNPlex14343722835710020057
Chang et al. [17]2014ChineseLiver cancerSNPlex15848743635710020057
Kullmann et al. [16]2013CaucasianBreast cancerTaqMan221193280221180356

Abbreviations: W, wild-type allele; M, mutant-type allele.
3.2. Quantitative Data Synthesis

The results for the association of DNMT1 rs16999593 (T/C) with cancer risk are summarized in Table 2. Overall, neither the heterozygous nor dominant genetic models found significant associations between rs16999593 (T/C) and cancer risk (TC versus TT: OR = 1.29, 95% CI = 0.90–1.84, ; TC + CC versus TT: OR = 1.28, 95% CI = 0.93–1.77, ). The allele analysis also found no significant association (C allele versus T allele: OR = 1.18, 95% CI = 0.96–1.45, ). For the subgroup analysis according to cancer type (Figure 2), rs16999593 (T/C) was consistently associated with increased risk of gastric cancer (TC versus TT: OR = 1.36, 95% CI = 1.14–1.61, ; TC + CC versus TT: OR = 1.36, 95% CI = 1.15–1.60, ; C allele versus T allele: OR = 1.28, 95% CI = 1.11–1.47, ), but no significant association was found with breast cancer. For the different genotyping methods, rs16999593 (T/C) demonstrated increased risk of cancer in the sequencing subgroup but not in the MassARRAY subgroup.


Genetic modelGroup/subgroup Heterogeneity testStatistical modelTest for overall effect
(%)OR (95% CI)

CC versus TTOverall937.50.119F1.17 (0.92–1.49)0.213
Gastric cancer30.00.743F1.36 (0.93–1.99)0.117
Breast cancer348.10.146F0.93 (0.58–1.48)0.748
Sequencing430.10.232F1.33 (0.90–1.95)0.149
MassARRAY366.10.052R1.01 (0.53–1.93)0.968

TC versus TTOverall989.70<0.001R1.29 (0.90–1.84)0.163
Gastric cancer300.000.540F1.36 (1.141.61)0.001
Breast cancer395.90<0.001R1.53 (0.62–3.80)0.360
Sequencing490.30<0.001R2.06 (1.163.65)0.013
MassARRAY385.400.001R0.84 (0.49–1.43)0.517

(TC + CC) versus TTOverall988.60<0.001R1.28 (0.93–1.72)0.135
Gastric cancer300.000.720F1.36 (1.151.60)<0.001
Breast cancer395.50<0.001R1.45 (0.62–3.40)0.388
Sequencing488.40<0.001R1.99 (1.203.28)0.007
MassARRAY383.600.002R0.88 (0.55–1.41)0.603

CC versus (TC + TT)Overall948.70.049R1.03 (0.72–1.49)0.861
Gastric cancer30.000.635F1.22 (0.84–1.78)0.303
Breast cancer370.50.034R0.49 (0.13–1.76)0.274
Sequencing462.90.044R1.00 (0.49–2.04)0.998
MassARRAY365.80.054R1.10 (0.59–2.05)0.767

C allele versus T alleleOverall981.40<0.001R1.18 (0.95–1.45)0.127
Gastric cancer300.000.936F1.28 (1.111.47)0.001
Breast cancer391.50<0.001R1.18 (0.71–1.97)0.529
Sequencing466.300.030R1.53 (1.261.95)<0.001
MassARRAY381.100.005R0.96 (0.67–1.36)0.805

Abbreviations: R, random effect model; F, fixed effect model.

The results for the association of DNMT1 rs2228611 (G/A) with cancer risk are summarized in Table 3. Overall, the GA genotype was not significantly associated with risk of cancer compared with the GG genotype (OR = 1.05, 95% CI = 0.92–1.21, ), and the GA + AA genotype was not related to cancer risk compared with the GG genotype (OR = 1.05, 95% CI = 0.96–1.15, ). Similarly, no significant association was observed in the allele analysis (A allele versus G allele: OR = 1.02, 95% CI = 0.95–1.10, ). In the subgroup analysis according to cancer type (Figure 3), the rs2228611 (G/A) was associated with higher risk of breast cancer (GA versus GG: OR = 1.17, 95% CI = 1.03–1.33, ; GA + AA versus GG: OR = 1.13, 95% CI = 1.00–1.28, ). A similar result was found in the MALDI-TOF subgroup (GA versus GG: OR = 1.20, 95% CI = 1.03–1.41, ) in the analysis according to different genotyping methods. For the gastric cancer and PCR-RFLP subgroups, no significant associations were found in any of the compared genetic models.


Genetic modelGroup/subgroupStudies Heterogeneity testStatistical modelTest for overall effect
(%)OR (95% CI)

AA versus GGOverall110.000.925F0.99 (0.84–1.19)0.898
Gastric cancer30.000.774F0.74 (0.49–1.13)0.165
Breast cancer40.000.979F0.98 (0.78–1.22)0.848
PCR–RFLP40.000.880F1.04 (0.76–1.42)0.803
MALDI-TOF30.000.511F0.87 (0.65–1.17)0.360

GA versus GGOverall1141.000.075R1.05 (0.92–1.21)0.445
Gastric cancer30.000.461F1.07 (0.86–1.33)0.522
Breast cancer435.600.198F1.17 (1.031.33)0.016
PCR–RFLP464.000.040R1.05 (0.73–1.52)0.782
MALDI-TOF30.000.910F1.20 (1.031.41)0.022

(GA + AA) versus GGOverall111.800.425F1.05 (0.96–1.15)0.284
Gastric cancer30.000.618F1.02 (0.83–1.26)0.860
Breast cancer41.500.385F1.13 (1.001.28)0.043
PCR–RFLP451.700.102F1.06 (0.87–1.29)0.542
MALDI-TOF30.000.872F1.14 (0.98–1.33)0.087

AA versus (GA + GG)Overall110.000.596F0.97 (0.83–1.13)0.671
Gastric cancer30.000.535F0.76 (0.51–1.12)0.169
Breast cancer40.000.813F0.90 (0.73–1.12)0.351
PCR–RFLP40.000.779F0.99 (0.76–1.29)0.933
MALDI-TOF30.000.501F0.80 (0.60–1.06)0.126

A allele versus G alleleOverall110.000.978F1.02 (0.95–1.10)0.532
Gastric cancer30.000.863F0.96 (0.82–1.14)0.660
Breast cancer40.000.861F1.06 (0.96–1.16)0.249
PCR–RFLP40.000.530F1.03 (0.90–1.18)0.696
MALDI-TOF30.000.745F1.04 (0.93–1.17)0.494

R: random effect model; F: fixed effect model.

The results for the association of DNMT1 rs2228612 (A/G) with cancer risk are summarized in Table 4 and Figure 4. Significant association with cancer risk was observed in the recessive model (GG versus AG + AA: OR = 1.29, 95% CI = 1.06–1.56, ), but no significant association was revealed in the allele analysis (G allele versus A allele: OR = 1.00, 95% CI = 0.83–1.20, ).


Genetic model Heterogeneity testStatistical modelTest for overall effect
(%)OR (95% CI)

GG versus AA19.200.292F1.20 (0.97–1.49)0.088
AG versus AA60.300.039R0.81 (0.61–1.08)0.156
(GG + AG) versus AA62.70.030R0.87 (0.66–1.14)0.310
GG versus (AA + AG)11.500.340F1.29 (1.061.56)0.009
G allele versus A allele58.700.046R1.00 (0.83–1.20)0.980

R: random effect model; F: fixed effect model.
3.3. Heterogeneity Test and Sensitivity Analysis

In most of the comparisons of DNMT1 rs16999593 and rs2228612 polymorphisms and one comparison of DNMT1 rs2228611, significant heterogeneity was observed. We next performed a leave-one-out sensitivity analysis. The results show that no individual study significantly affected the pooled OR (figure not shown), suggesting that the results of the meta-analysis were robust.

3.4. Publication Bias

Begg’s test and Egger’s test were used to quantitatively evaluate the publication bias of the selected studies; the details are listed in Table 5. For the associations of DNMT1 rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G) with cancer risk, rs2228612 (A/G) showed publication bias (GG versus AA; G allele versus A allele) and rs16999593 (T/C) showed publication bias in the comparison with the recessive model.


PolymorphismCompared genotypeBegg’s testEgger’s test
-value value-value value

DNMT1 rs16999593 T/CCC versus TT0.940.348−2.000.085
TC versus TT0.100.9170.030.976
(TC + CC) versus TT0.100.9170.020.982
CC versus (TC + TT)1.980.048−2.720.030
C allele versus T allele0.100.917−0.450.669

DNMT1 rs2228611 G/AAA versus GG1.400.161−0.990.348
GA versus GG0.780.436−0.650.530
(GA + AA) versus GG0.780.436−0.690.505
AA versus (GA + GG)0.470.640−0.610.556
A allele versus G allele0.930.3501.170.273

DNMT1 rs2228612 (A/G)GG versus AA1.710.086−3.970.029
AG versus AA0.240.806−2.860.065
(GG + GA) versus AA0.730.462−3.810.032
GG versus (AA + AG)0.730.462−1.370.263
G allele versus A allele2.200.027−4.260.024

4. Discussion

DNMT1, the major methyltransferase in mammals, lies in the replication fork and methylates newly synthesized DNA strands directly in S phase of DNA replication sites [22], which is essential for epigenetic inheritance. Regional aberrant DNA hypermethylation has been identified as a possible mechanism of inactivation of tumor suppressor genes [23]. Many studies have indicated that the overexpression of DNMT1 could silence vital tumor suppressor genes such as APC, P16, and RUNX3 through DNA methylation [24, 25]. Therefore, DNMT1 might be implicated in the occurrence, development, and prognosis of multiple types of cancer.

Polymorphisms have been identified as a powerful tool for predicting hereditary susceptibility of some complex diseases including cancer. However, previous individual studies about the association between DNMT1 polymorphisms and cancer risk were not only limited but also inconclusive. To our knowledge, this is the first comprehensive meta-analysis investigating the possible correlations of SNPs rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G) in DNMT1 with risk of overall cancer and specific cancer types, which is anticipated to shed light on the role of DNMT1 polymorphisms in carcinogenesis.

SNP rs2228612 (A/G) causes an isoleucine to phenylalanine substitution at amino acid 327 in the DNMT1 protein, which may alter the function of DNMT1 and influence its effect in the carcinogenesis. In this meta-analysis, we found that DNMT1 rs2228612 (A/G) was associated with risk of overall cancer in the recessive model. However, only three articles with small-scale studies were available for analysis; therefore, the results should to be interpreted with caution.

We did not find significant association between SNP rs16999593 (T/C) and overall cancer risk in any genetic comparison. Different types of cancer have distinct initiation and progression mechanisms, in which polymorphisms in key genes play critical roles. This meta-analysis elucidated that the DNMT1 rs16999593 (T/C) polymorphism was associated with different cancer types. In the subgroup analysis according to cancer type, the TC genotype of rs16999593 (T/C) was associated with risk of gastric cancer, but not breast cancer. Extensive evidence has suggested that DNA methylation is involved in the initiation and progression of gastric cancer and increased expression of DNMT1 had been confirmed to be related to gastric cancer [25]. The AKT-NFκB and STAT3 signaling pathways can upregulate DNMT1 expression, which could cause aberrant DNA methylation of tumor suppressor genes and lead to gastric cancer [26, 27]. Therefore, SNP rs16999593 (T/C), which causes a histidine to arginine substitution at 97 positions of the amino acid sequence, might affect the function of DNMT1, thus increasing susceptibility to gastric cancer. The subgroup of breast cancer involved two types of breast cancer: sporadic triple-negative breast cancer (TNBC) [15] and infiltrating ductal beast carcinoma (IDBC) [6]. The TC genotype of rs16999593 (T/C) was related to increased TNBC risk but decreased IDBC risk. Therefore, DNMT1 might have diverse functions in different types of breast cancer. Further studies of the effects of DNMT1 polymorphisms on specific breast cancer types are still needed. In addition, only in the subgroup of sequencing, DNMT1 rs16999593 (T/C) were constantly associated with increased cancer risk in all compared genetic models, indicating that different genotype detecting methods might influence the results.

According to the functional prediction tool F-SNP (http://compbio.cs.queensu.ca/F-SNP/), SNP rs2228611 (G/A) may change the regulation of DNMT1 splicing by leading to a synonymous mutation at amino acid 463. Multiple transcript variants of DNMT1 gene as a result of alternative splicing have been found. Therefore, we speculated that the rs2228611 (G/A) might influence the process of carcinogenesis by regulating the pattern of alternative splicing of DNMT1. Here, we did not find any significant associations between DNMT1 rs2228611 (G/A) with altered risk of cancer in any genetic model. However, in the subgroup analysis, individuals with the GA genotype of rs2228611 (G/A) were associated with higher risk of breast cancer in both heterozygous and dominant models. In addition, individuals with the GA genotype of rs2228611 (G/A) had decreased risk in one study on esophageal cancer [14], which was opposite to the results for breast cancer. This reverse outcome may be because various types of cancer have different mechanisms of carcinogenesis. Future studies on different types of cancer may help to better understand these findings.

Some limitations of our meta-analysis should be noted. Firstly, the number of studies was not sufficiently large, especially for subgroup analysis of DNMT1 rs2228612 (A/G). Secondly, the languages of the publications were limited to English and Chinese. Thirdly, although this meta-analysis was based on the whole population, most studies were from Chinese populations, except for one Iranian case and one Polish case for rs2228611 (G/A) and another one Caucasian case for rs2228612 (A/G), which showed the same results with the Chinese population. So this study had a certain universality, especially for Chinese population. Finally, publication bias was found in two comparisons of rs2228612 (A/G) and one comparison of rs16999593 (T/C).

5. Conclusion

The DNMT1 rs2228612 (A/G) GG genotype may be associated with increased risk of cancer compared with the AA + AG genotype. SNP rs16999593 (T/C) is significantly associated with gastric cancer risk while SNP rs2228611 (G/A) is significantly related to breast cancer risk. Further large-scale and well-designed investigations including different cancers are required to verify the findings of this study.

Disclosure

The authors alone are responsible for the content and writing of the paper.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Hao Li and Jing-wei Liu performed statistical analysis and data interpretation and wrote the paper. Li-ping Sun and Yuan Yuan conceived this study and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This study was supported by the National Key R&D Program, Grant 2016YFC1303200, and the Key Laboratory of Cancer Intervention in Liaoning Province, Grant LS201605.

Supplementary Materials

PRISMA is an evidence-based minimum set of items for reporting in systematic reviews and meta-analyses.

  1. Supplementary Material

References

  1. K. D. Robertson, “DNA methylation, methyltransferases, and cancer,” Oncogene, vol. 20, no. 24, pp. 3139–3155, 2001. View at: Publisher Site | Google Scholar
  2. A. Razin and A. D. Riggs, “DNA methylation and gene function,” Science, vol. 210, no. 4470, pp. 604–610, 1980. View at: Publisher Site | Google Scholar
  3. M. W. Łuczak and P. P. Jagodziński, “The role of DNA methylation in cancer development,” Folia Histochemica et Cytobiologica, vol. 44, no. 3, pp. 143–154, 2006. View at: Google Scholar
  4. M. T. McCabe, J. C. Brandes, and P. M. Vertino, “Cancer DNA methylation: molecular mechanisms and clinical implications,” Clinical Cancer Research, vol. 15, no. 12, pp. 3927–3937, 2009. View at: Publisher Site | Google Scholar
  5. J. Turek-Plewa and P. P. Jagodziński, “The role of mammalian DNA methyltransferases in the regulation of gene expression,” Cellular and Molecular Biology Letters, vol. 10, no. 4, pp. 631–647, 2005. View at: Google Scholar
  6. G. Xiang, F. Zhenkun, C. Shuang et al., “Association of DNMT1 gene polymorphisms in exons with sporadic infiltrating ductal breast carcinoma among chinese han women in the heilongjiang province,” Clinical Breast Cancer, vol. 10, no. 5, pp. 373–377, 2010. View at: Publisher Site | Google Scholar
  7. M. Y. Sun, Association study of single nucleotide polymorphisms in estrogen synthesis, metabolism-related genes, and DNMTs with the susceptibility of breast cancer among Han Chinese women [M.S. thesis], Nanfang Medical University, Guangzhou, China, 2012.
  8. F. Khatami, B. Noorinayer, S. Ghiasi, R. Mohebi, M. Hashemi, and M. R. Zali, “Lack of effects of single nucleotide polymorphisms of the DNA methyltransferase 1 gene on gastric cancer in Iranian patients: a case control study,” Asian Pacific Journal of Cancer Prevention, vol. 10, no. 6, pp. 1177–1182, 2009. View at: Google Scholar
  9. J. Jiang, Z. Jia, D. Cao et al., “Polymorphisms of the DNA methyltransferase 1 associated with reduced risks of helicobacter pylori infection and increased risks of gastric atrophy,” PLoS ONE, vol. 7, no. 9, Article ID e46058, 2012. View at: Publisher Site | Google Scholar
  10. X.-X. Yang, X.-Q. He, F.-X. Li, Y.-S. Wu, Y. Gao, and M. Li, “Risk-association of DNA methyltransferases polymorphisms with gastric cancer in the Southern Chinese population,” International Journal of Molecular Sciences, vol. 13, no. 7, pp. 8364–8378, 2012. View at: Publisher Site | Google Scholar
  11. B.-S. He, Y.-Q. Pan, and C.-B. Zhu, “Polymorphisms of DNA methyltransferases and the risk of prostate cancer,” Zhonghua Nan Ke Xue, vol. 20, no. 12, pp. 1077–1081, 2014. View at: Google Scholar
  12. L. Wang, “Correlation of DNA methyctransferase 1 gene polymorphisms and passive smoking with cervical cancer,” International Journal of Gynecology & Obstetrics, no. 6, pp. 663–666, 2014. View at: Google Scholar
  13. Y. Gao, “Association of Dnmt 1 single-mucleotide polymorphisms and risk of gastric caner,” Chinese Journal of Cancer Prevention and Treatment, no. 6, pp. 394–397, 2015. View at: Google Scholar
  14. H. Li, “Association of polymorphisms of DNMT1 and DNMT3B with risk of esophageal cancer,” Labeled Immunoassays and Clinical Medicine, no. 12, pp. 1214–1220, 2015. View at: Google Scholar
  15. R. Tao, Z. Chen, P. Wu et al., “The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females,” Tumor Biology, vol. 36, no. 12, pp. 9849–9855, 2015. View at: Publisher Site | Google Scholar
  16. K. Kullmann, M. Deryal, M. F. Ong, W. Schmidt, and U. Mahlknecht, “DNMT1 genetic polymorphisms affect breast cancer risk in the central European Caucasian population,” Clinical Epigenetics, vol. 5, no. 1, article 7, 2013. View at: Publisher Site | Google Scholar
  17. S.-C. Chang, P.-Y. Chang, B. Butler et al., “Single nucleotide polymorphisms of one-carbon metabolism and cancers of the esophagus, stomach, and liver in a Chinese population,” PLoS ONE, vol. 9, no. 10, Article ID e109235, 2014. View at: Publisher Site | Google Scholar
  18. A. Mostowska, S. Sajdak, P. Pawlik, M. Lianeri, and P. P. Jagodzinski, “DNMT1, DNMT3A and DNMT3B gene variants in relation to ovarian cancer risk in the Polish population,” Molecular Biology Reports, vol. 40, no. 8, pp. 4893–4899, 2013. View at: Publisher Site | Google Scholar
  19. J. Xi, Y. Su, A. B. Fadiel et al., “Association of physical activity and polymorphisms in FGFR2 and DNA methylation related genes with breast cancer risk,” Cancer Epidemiology, vol. 38, no. 6, pp. 708–714, 2014. View at: Publisher Site | Google Scholar
  20. W. Lin, Y. L. Cen, Y. Lin et al., “Joint effects between urinary selenium and polymorphisms in methylation related genes on breast cancer risk,” Neoplasma, vol. 62, no. 3, pp. 491–499, 2015. View at: Publisher Site | Google Scholar
  21. S.-M. Yang, C.-Y. Huang, H.-S. Shiue et al., “Combined effects of DNA methyltransferase 1 and 3A polymorphisms and urinary total arsenic levels on the risk for clear cell renal cell carcinoma,” Toxicology and Applied Pharmacology, vol. 305, pp. 103–110, 2016. View at: Publisher Site | Google Scholar
  22. C. J. Klein, M.-V. Botuyan, Y. Wu et al., “Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss,” Nature Genetics, vol. 43, no. 6, pp. 595–600, 2011. View at: Publisher Site | Google Scholar
  23. S. B. Baylin, M. Makos, J. Wu et al., “Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression,” Cancer Cells, vol. 3, no. 10, pp. 383–390, 1991. View at: Google Scholar
  24. C. A. Eads, A. E. Nickel, and P. W. Laird, “Complete genetic suppression of polyp formation and reduction of CPG-island hypermethylation in ApcMin/+ Dnmt1-hypomorphic mice,” Cancer Research, vol. 62, no. 5, pp. 1296–1299, 2002. View at: Google Scholar
  25. W. Chen, N. Gao, Y. Shen, and J.-N. Cen, “Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer,” Journal of Gastroenterology and Hepatology (Australia), vol. 25, no. 4, pp. 823–831, 2010. View at: Publisher Site | Google Scholar
  26. B.-G. Zhang, L. Hu, M.-D. Zang et al., “Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFκB pathway in gastric cancer development,” Oncotarget, vol. 7, no. 9, pp. 9788–9800, 2016. View at: Publisher Site | Google Scholar
  27. Q. Zhang, H. Y. Wang, A. Woetmann, P. N. Raghunath, N. Odum, and M. A. Wasik, “STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes,” Blood, vol. 108, no. 3, pp. 1058–1064, 2006. View at: Publisher Site | Google Scholar

Copyright © 2017 Hao Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1037 Views | 304 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.